Ken Griffin Alkermes Plc. Transaction History
Citadel Advisors LLC
- $618 Billion
- Q3 2025
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Alkermes Plc. stock. As of the latest transaction made, Citadel Advisors LLC holds 704,834 shares of ALKS stock, worth $20.5 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
704,834
Previous 37,423
1783.42%
Holding current value
$20.5 Million
Previous $1.07 Million
1876.17%
% of portfolio
0.0%
Previous 0.0%
Shares
31 transactions
Others Institutions Holding ALKS
# of Institutions
400Shares Held
176MCall Options Held
901KPut Options Held
400K-
Black Rock Inc. New York, NY29.1MShares$845 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.2MShares$528 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD10.2MShares$297 Million0.03% of portfolio
-
State Street Corp Boston, MA8.54MShares$248 Million0.01% of portfolio
-
Baker Bros. Advisors LP New York, NY8.09MShares$235 Million1.98% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $4.77B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...